Irinotecan for metastatic colorectal cancer

Article Abstract:

Intravenous irinotecan (Camptosar) has been approved for the treatment of metastatic colorectal cancer after other regimens fail. Irinotecan may have a palliative and life-prolonging impact on some patients not responding to fluorouracil. However, the cost of the drug and its toxic effects are high. Adverse reactions include severe diarrhea, gastrointestinal problems, myelosuppression, and related fatal sepsis. The value of irinotecan in combination with fluorouracil is unknown.

Colorectal cancer, Camptosar (Medication)

---

Gemcitabine for treatment of pancreatic cancer

Article Abstract:

Intravenous gemcitabine (Gemzar) may somewhat benefit patients with pancreatic cancer. Intravenously administered, gemcitabine reduces pain, slightly prolongs survival, and improves overall functions. Minor side effects include nausea, vomiting, and other mild reactions. Bone marrow production will decrease at high doses. Although pancreatic cancer responds poorly to chemotherapy, gemcitabine performed better in comparison to flourouracil.

Health aspects, Pancreatic cancer, Nucleoside analogs, Gemzar (Medication)

---

Similar abstracts:

• Abstracts: Altretamine for ovarian cancer. Levamisole with fluorouracil for colon cancer
• Abstracts: Moricizine for cardiac arrhythmias. Radiofrequency catheter ablation for treatment of cardiac arrhythmias. Dexrazoxane for cardiac protection against doxorubicin
• Abstracts: von Willebrand factor in head and neck cancer. Psychosexual functioning after the treatment of cancer of the vulva
• Abstracts: Clinical significance of nuclear DNA content in pancreatic carcinoma. KI-ras oncogene mutations in non-HPV-associated anal carcinoma
• Abstracts: von Willebrand factor in head and neck cancer. Intraoperative radiation therapy for recurrent head and neck cancer

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.